April 29, 2004
Immune Response shares soared 24 percent Thursday after the maker of immune-based therapies reported encouraging trial results its NeuroVax multiple sclerosis vaccine.
Specifically, 94 percent of patients tested in an early-stage NeuroVax trial showed a peptide-specific immune response, according to Immune Response.
The Carlsbad, Calif.-based firm's stock jumped 39 cents, or 24 percent, to close at $2.02, after climbing as high as $2.45 in morning trading.
NeuroVax uses a combination of T-cell receptor peptides from three families, Immune Response said. The peptides are used to block interactions between cells and can potentially suppress multiple sclerosis in patients afflicted with the disease.
In a Phase I/II clinical trial of NeuroVax, 94 percent of patients treated with the vaccine showed a disease-specific immune response, meaning their immune systems responded appropriately and recognized pathogenic T cells.
"We will continue to pursue development of NeuroVax in multiple sclerosis as both a monotherapy and in combination with currently approved patients," said John Bonfiglio, Immune Response's chief executive.
No serious side effects from NeuroVax were reported and the only adverse
effects were injection-site reactions, the company noted.
Copyright © 2004, MarketWatch